Professor Brian MacCraith:

I thank Deputy Lahart for his comments. I spoke to the European lead of Johnson & Johnson. The name of its vaccine is Janssen. It is expecting to announce the clinical trial results in the coming days and to submit to the Food & Drug Administration, FDA, in the first instance in early February. What normally happens is that the submissions to the European Medicines Agency, EMA, would happen not too long after that. We are hopeful of a positive outcome for Janssen. It is very attractive because it is a single dose vaccine. We hope there will be a positive outcome some time in March but these things remain uncertain.